Answers are grounded in this paper and cite their sources.
The majority of cancer patients assume concomitant medications for the treatment of cancer-related symptoms or co-morbidities. As immune checkpoint inhibitors expand in the treatment of a widening range of malignancies, drug-drug interactions have become an area of increasing interest due to the potential for some concomitant medications to exert immune-modulatory effects and influence outcomes from immunotherapy. Here, we review the evidence supporting this association across selected drug classes including antibiotics, proton pump inhibitors, metformin, and opioids.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: